EP1389233A4 - Anticorps monoclonaux a ligands anti-rank convenant au traitement de troubles induits par des ligands rank - Google Patents

Anticorps monoclonaux a ligands anti-rank convenant au traitement de troubles induits par des ligands rank

Info

Publication number
EP1389233A4
EP1389233A4 EP02736659A EP02736659A EP1389233A4 EP 1389233 A4 EP1389233 A4 EP 1389233A4 EP 02736659 A EP02736659 A EP 02736659A EP 02736659 A EP02736659 A EP 02736659A EP 1389233 A4 EP1389233 A4 EP 1389233A4
Authority
EP
European Patent Office
Prior art keywords
rank ligand
treatment
monoclonal antibodies
mediated disorders
antibodies useful
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02736659A
Other languages
German (de)
English (en)
Other versions
EP1389233A1 (fr
Inventor
Raymond W Sweet
Mark A Tornetta
Trevor Wattam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Ltd
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd, SmithKline Beecham Corp filed Critical SmithKline Beecham Ltd
Publication of EP1389233A1 publication Critical patent/EP1389233A1/fr
Publication of EP1389233A4 publication Critical patent/EP1389233A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
EP02736659A 2001-05-18 2002-05-03 Anticorps monoclonaux a ligands anti-rank convenant au traitement de troubles induits par des ligands rank Withdrawn EP1389233A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29203101P 2001-05-18 2001-05-18
US292031P 2001-05-18
PCT/US2002/014246 WO2002095012A1 (fr) 2001-05-18 2002-05-03 Anticorps monoclonaux a ligands anti-rank convenant au traitement de troubles induits par des ligands rank

Publications (2)

Publication Number Publication Date
EP1389233A1 EP1389233A1 (fr) 2004-02-18
EP1389233A4 true EP1389233A4 (fr) 2006-03-08

Family

ID=23122878

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02736659A Withdrawn EP1389233A4 (fr) 2001-05-18 2002-05-03 Anticorps monoclonaux a ligands anti-rank convenant au traitement de troubles induits par des ligands rank

Country Status (3)

Country Link
EP (1) EP1389233A4 (fr)
JP (1) JP2005515752A (fr)
WO (1) WO2002095012A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001293030B2 (en) 2000-09-22 2007-07-19 Immunex Corporation Screening assays for agonists or antagonists of receptor activat or of NF-kB
US8765388B2 (en) 2007-08-10 2014-07-01 Agency For Science, Technology And Research (A*Star) VHZ for diagnosis and treatment of cancer
US9580513B2 (en) 2008-08-08 2017-02-28 Agency For Science, Technology And Research (A*Star) VHZ for diagnosis and treatment of cancers
CN102741286B (zh) * 2010-03-26 2013-12-25 刘庆法 以pae技术开发的抗人rankl单抗及其应用
EP2692359B1 (fr) * 2011-03-31 2017-06-07 Oriental Yeast Co., Ltd. Potentialisateur d'immunité anticancéreuse contenant un antagoniste de rankl

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001091793A1 (fr) * 2000-05-26 2001-12-06 Smithkline Beecham Corporation Anticorps monoclonaux contre le ligand rank, utilises pour le traitement d'etats pathologiques lies au ligand rank
WO2002015846A2 (fr) * 2000-08-21 2002-02-28 Smithkline Beecham Corporation Anticorps monoclonaux à ligands anti-rank convenant au traitement de troubles à médiation des ligands des rank

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6392019B1 (en) * 1997-11-22 2002-05-21 John Ford Antibodies specific for EGF motif proteins

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001091793A1 (fr) * 2000-05-26 2001-12-06 Smithkline Beecham Corporation Anticorps monoclonaux contre le ligand rank, utilises pour le traitement d'etats pathologiques lies au ligand rank
WO2002015846A2 (fr) * 2000-08-21 2002-02-28 Smithkline Beecham Corporation Anticorps monoclonaux à ligands anti-rank convenant au traitement de troubles à médiation des ligands des rank

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
MENAA C ET AL: "Enhanced RANK ligand expression and responsivity of bone marrow cells in Paget's disease of bone", JOURNAL OF CLINICAL INVESTIGATION, NEW YORK, NY, US, vol. 105, no. 12, June 2000 (2000-06-01), pages 1833 - 1838, XP002278692, ISSN: 0021-9738 *
NAGAI MASAZUMI ET AL: "Cancer cells responsible for humoral hypercalcemia express mRNA encoding a secreted form of ODF/TRANCE that induces osteoclast formation", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 269, no. 2, 16 March 2000 (2000-03-16), pages 532 - 536, XP002278694, ISSN: 0006-291X *
See also references of WO02095012A1 *
TANAKA Y ET AL: "INTERCELLULAR ADHESION MOLECULE 1 DISCRIMINATES FUNCTIONALLY DIFFERENT POPULATIONS OF HUMAN OSTEOBLASTS: CHARACTERISTIC INVOLVEMENT OF CELL CYCLE REGULATORS", JOURNAL OF BONE AND MINERAL RESEARCH, NEW YORK, NY, US, vol. 15, no. 10, October 2000 (2000-10-01), pages 1912 - 1923, XP009030306, ISSN: 0884-0431 *

Also Published As

Publication number Publication date
JP2005515752A (ja) 2005-06-02
WO2002095012A1 (fr) 2002-11-28
EP1389233A1 (fr) 2004-02-18

Similar Documents

Publication Publication Date Title
EP1283721A4 (fr) Anticorps monoclonaux contre le ligand rank, utilises pour le traitement d'etats pathologiques lies au ligand rank
EP1458411A4 (fr) Anticorps monoclonaux ligands anti-rank convenant au traitement de troubles lies aux ligands de rank
EP1482972A4 (fr) Traitement des troubles immunologiques au moyen des anticorps anti-cd30
IL158831A0 (en) METHODS OF ADMINISTERING ANTI-TNFalpha ANTIBODIES
IL214263A0 (en) Therapeutic human anti-il-1r1 monoclonal antibody
PL398596A1 (pl) Preparat zawierający ludzkie przeciwciała do leczenia zaburzeń związanych z TNF-α
PL378412A1 (pl) Cząsteczki przeciwciał o specyficzności względem ludzkiej IL-1ß
IL206980A0 (en) Antibodies that bind human interleukin-18 and methods of making and using
IL165193A (en) Humanized immunomodulatory monoclonal antibodies and use thereof for the treatment of neoplastic disease
AU2003290158A8 (en) Variable fragments of single-chain camelide antibodies and uses thereof for diagnosing and treating various pathologies
EP1487471A4 (fr) Techniques de traitement de maladies auto-immunes et reactifs associes
PL354112A1 (en) Application of anti-ctla-4 antibodies
IL205511A0 (en) Methods and compositions for the production of monoclonal antibodies
ZA200604074B (en) Anti-IGFR1 antibody therapeutic combinations
PL373246A1 (en) Use of ep4 receptor ligands in the treatment of il-6 involved diseases
PL374118A1 (en) Interleukin-1 receptors in the treatment of diseases
IL175610A0 (en) Methods and reagents for the treatment of inflammatory disorders
EP1448205A4 (fr) Combinaisons permettant le traitement des troubles inflammatoires
EP1442062A4 (fr) Methodes de traitement du carcinome
IL160561A0 (en) Method and composition for treating immune complex associated disorders
AU2002364607A8 (en) Novel ligand involved in the transmigration of leukocytes .
EP1455812A4 (fr) Traitement aux anticorps monoclonaux anti-cd40 antagonistes utilise pour traiter la sclerose en plaques
EP1389233A4 (fr) Anticorps monoclonaux a ligands anti-rank convenant au traitement de troubles induits par des ligands rank
EP1472273A4 (fr) Compositions et methodes de traitement de maladies d'origine immune
AU2002309645A1 (en) Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20031120

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SMITHKLINE BEECHAM PLC

Owner name: SMITHKLINE BEECHAM CORPORATION

A4 Supplementary search report drawn up and despatched

Effective date: 20060120

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/68 20060101ALI20060116BHEP

Ipc: C07K 16/28 20060101ALI20060116BHEP

Ipc: C07H 21/04 20060101ALI20060116BHEP

Ipc: C07K 16/00 20060101ALI20060116BHEP

Ipc: G01N 33/53 20060101ALI20060116BHEP

Ipc: C12N 5/06 20060101AFI20021130BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060419